Rna Diagnostics

Name

Rna Diagnostics

Legal name

Rna Diagnostics Inc.

Website

https://rnadiagnostics.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)

Keywords

• Molecular diagnostics
• Cancer biomarker testing
• Neoadjuvant treatment monitoring
• Predictive diagnostics
• Clinical stage diagnostics

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Veridapt DX Laboratory Test Services: Molecular diagnostic testing services for cancer therapy response evaluation. Oncologists submit tumor biopsy samples during neoadjuvant treatment for RNA disruption analysis. Revenue generated through laboratory service fees per test.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Rna Diagnostics offers the Veridapt DX predictive biomarker test (also branded as the RNA Disruption Assay / RDA), a laboratory diagnostic service that measures ribosomal RNA disruption in solid tumor biopsy samples during neoadjuvant cancer treatment. The platform uses capillary electrophoresis instrumentation and a proprietary RNA Disruption Index (RDI) algorithm to classify patients into three response zones, enabling oncologists to optimize therapy as early as five weeks into treatment. Testing is performed in the company's CLIA-certified, A2LA-accredited laboratory in Sudbury, Ontario, serving oncologists and cancer centers globally.

Product overview

Rna Diagnostics offers a single unified diagnostic platform product: Veridapt DX™ (also marketed as the RNA Disruption Assay or RDA™). This predictive biomarker test measures ribosomal RNA disruption in solid tumor cells during neoadjuvant cancer treatment to predict therapy efficacy. The platform uses capillary electrophoresis instrumentation and a proprietary algorithm to generate an RNA Disruption Index (RDI) score, classifying patients into three response zones. Veridapt DX is currently in late-stage clinical validation through the BREVITY trial and is not yet commercially launched.

Differentiator

Problem solved

Functional benefit

Brands

• Veridapt DX: Predictive biomarker platform technology (RNA Disruption Assay) for optimizing early-stage cancer therapy. Measures solid tumor response to neoadjuvant cancer treatment with >93% Negative Predictive Value.
• RNA Disruption Assay (RDA)

Products and services

• Veridapt DX™ (RNA Disruption Assay)

Quantifiable outcome

• Negative Predictive Value >93% for predicting therapy non-response during treatment
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Clinical Trials IrelandcoreStrategic or Co-development PartnerCollaborating on the SHAMROCK adaptive trial for high-risk HER2-positive breast cancer patients. Clinical Trials Ireland manages the trial evaluating Veridapt DX platform to identify super-responders and adjust treatments.
• Cancer Research UK / University of BirminghamminorStrategic or Co-development PartnerROSCO study (Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer) led by scientists at Cancer Research UK and University of Birmingham. Veridapt DX platform deployed in a substudy evaluating genetic markers to predict chemotherapy response.
• Health Sciences North Research InstitutecoreStrategic or Co-development PartnerLocation of Rna Diagnostics' world-class CLIA-certified laboratory in Sudbury, Ontario for Veridapt DX testing services.
• Institute of Cancer Research (Oslo University Hospital)minorStrategic or Co-development PartnerCollaborated on retrospective study of 132 patients from NeoAva clinical trial. Research led by Dr. Olav Engebråten demonstrating RNA disruption assay's value in predicting chemotherapy outcomes for early-stage breast cancer.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Exact Sciences: Commercial-stage molecular diagnostics company whose Oncotype DX test is widely used in breast cancer treatment decision-making. Direct comparable as both companies offer predictive biomarker tests guiding neoadjuvant or adjuvant therapy decisions in breast cancer.
• Agendia: Oncology diagnostics company whose MammaPrint test provides genomic profiling to inform breast cancer treatment. Closely comparable to Rna Diagnostics as both target early-stage breast cancer treatment personalization through molecular biomarker testing.
• NanoString Technologies: Developer of the Prosigna (PAM50) breast cancer gene expression test used to assess recurrence risk. Comparable in offering diagnostic tests that inform breast cancer treatment decisions using molecular profiling of tumor tissue.

Broad incumbents

• Foundation Medicine: Established molecular profiling company (acquired by Roche) offering comprehensive genomic profiling for solid tumors. Comparable as a broader oncology diagnostics player with tissue-based molecular testing, though targeting a wider indication portfolio than Rna Diagnostics.
• Caris Life Sciences: Provider of molecular profiling and AI-driven diagnostics (MI Profile, MI Cancer Seek) for oncology treatment selection. Comparable as a comprehensive molecular diagnostics competitor in the oncology treatment decision space.
• NeoGenomics: Specialized oncology reference laboratory offering a broad menu of molecular and genetic testing services. Comparable as a clinical-stage-to-commercial oncology testing infrastructure player with similar tissue-based testing approach.

Emerging players

• Guardant Health: Liquid biopsy company with oncology applications including treatment response monitoring (Guardant360). Comparable as a precision oncology diagnostics provider, though using blood-based rather than tissue-based biomarker methodology.
• Tempus: AI-driven precision medicine company offering molecular profiling and data analytics for oncology treatment decisions. Comparable as a technology-enabled oncology diagnostics provider, though operating at much larger scale with broader offerings.
• Natera: Molecular diagnostics company with oncology tests including Signatera for MRD monitoring. Comparable as a precision oncology diagnostics provider applying proprietary molecular biomarkers to inform cancer treatment decisions.
• Personalis: Cancer genomics company offering tumor profiling and MRD detection services. Comparable as a smaller/mid-stage molecular diagnostics company focused on oncology treatment decision support, though operating in different molecular biomarker categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rna-diagnostics-inc-/?viewAsMember=true
• Xx.com/rnadiagnostics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rna Diagnostics